Prognostic factors after chemoradiotherapy for patients with inoperable esophageal squamous cell carcinoma

Hepato-Gastroenterology

Volumn 53, Issue 69, 2006, Pages 366-371

  Kunisaki, Chikara ^a,b,c   Imada, Toshio ^a   Yamada, Roppei ^a   Hatori, Shinsuke ^a   Kinbara, Kazuhiro ^a   Watai, Kiichi ^a   Akiyama, Hirotoshi ^b   Nomura, Masato ^b   Matsuda, Goro ^b   Otsuka, Yuichi ^b   Ono, Hidetaka ^b   Shimada, Hiroshi ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Inoperable advanced esophageal cancer; p53 gene mutation; Predictive factors; Prognostic factors; Serum CYFRA level

Indexed keywords

CISPLATIN; CYTOKERATIN; FLUOROURACIL; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG TOLERANCE; ESOPHAGUS CANCER; FEMALE; GENE MUTATION; HUMAN; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REMISSION; SQUAMOUS CELL CARCINOMA;

AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KERATINS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33745458733     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Blot WJ, McLaughlin JK: The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26:2-8.
2. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer Statistics, 2001. CA Cancer J Clin 2001; 51:15-36.
3. Holscher AH, Bollschweiker E, Schneider PM, et al: Prognosis of early esophageal cancer: comparison between adeno-squamous cell carcinoma. Cancer 1995; 76:178-186.
4. Ando N, Ozawa S, Kitagawa Y, et al: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000; 232:225-232.
5. Baba M, Aikou T, Yoshinaka H, et al: Long-results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 1994; 219:310-316.
6. Akiyama H, Tsurumaru M, Udagawa H, et al: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220:346-372.
7. Osugi H, Takemura M, Takada N, Hirohashi K, Kinoshita H, Higashino M: Prognostic factors after oesophagectomy and extended lymphadenectomy for squamous oesophageal cancer. Br J Surg 2002; 89:909-913.
8. Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Eng J Med 1997; 337:161-167.
9. Ando N, Iizuka T, Ide H, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study JCOG9204. J Clin Oncol 2003; 21:4592-4596.
10. Kishi K, Doki Y, Miyata H, et al: Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 2002; 89:597-603.
11. Gibson MK, Abraham SC, Wu TT, et al: Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9:6461-6468.
12. Sobin LH, Wittekind CH: International Union Against Cancer TNM Classification of Malignant Tumours (6th Edition). New York; Wiley-Liss Inc., 2002.
13. Shimada H, Nabeya Y, Okazumi S, et al: Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003; 83:248-252.
14. Tamura G, Maesawa C, Suzuki Y, et al: p53 gene mutations in esophageal cancer detected by polymerase chain reaction single-strand confirmation polymorphism analysis. Jpn J Cancer Res 1992; 83:559-562.
15. Crosby TDL, Brewster AE, Borley A, et al: Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 2004; 90:70-75.
16. Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20:1167-1174.
17. Lowe SW, Ruley HE, Housman DE: P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-967.
18. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-810.
19. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, et al: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998; 83:7-18.
20. Yang B, Rice TW, Adelstein DJ, et al: Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma. Mod Pathol 1999; 12:251-256.
21. Takemura M, Osugi H, Takada N, Okuda E, Ueno M, Kinoshita H: The prognostic factors after radical esophagectomy for esophageal cancer with positive preoperative CEA. Hepatogastroenterology 2004; 51:159-162.
22. Kulpa J, Wojcik E, Reinfuss M, et al: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002; 48:1931-1937.
23. Yeh JJ, Liu FY, Hsu WH, et al: Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection. Lung 2002; 180:273-279.